In our study, in vivo genome-wide CRISPR screening and RNA-seq for clinical BC tissues identified ENO1 as a regulator of antitumor-tumor immunity and sensitivity to anti-PD-L1 therapy. The gene discussed is ENO1; the disease is neoplasm.